Yuhan Corporation

Mergers and acquisitions usually happen in major global biopharma markets as a way to gain new technologies, R&D or commercial portfolios, expand a business or to beef up supply networks. But in S

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Start-Up Nosis Partners Its AI Pl

The fourth quarter marked a continuation of weak earnings for many major South Korean pharma firms, hurt by factors including the continued impact of a long-running doctors’ protest against medical r

It is a time of challenges and uncertainties for the global biopharma industry and with the start of the second Trump Administration in the US, the international trade environment looks set to change